Carbidopa Brand Name– Lodosyn
What is Carbidopa
Carbidopa is a decarboxylase inhibitor that is used in combination with levodopa for the treatment of Parkinson’s disease.
The addition of carbidopa allows lower doses of levodopa to be used, allows for more rapid titration of and a smoother response to levodopa treatment, and minimizes certain adverse reactions attributed to levodopa therapy such as nausea and vomiting.
Patients with markedly irregular (on-off) responses to levodopa have not been shown to benefit from the addition of carbidopa.
The FDA approved carbidopa prior to 1982; however, carbidopa had been available to prescribers only through a compassionate use program.
Beginning in December 1999, carbidopa became available to US pharmacies for distribution.
- Parkinson’s disease
For the treatment of idiopathic Parkinson’s disease (paralysis agitans), post-encephalitic parkinsonism, or symptomatic parkinsonism following CNS injury due to carbon monoxide or manganese intoxication
- no Side Effects
Carbidopa has not been shown to have any overt pharmacodynamic actions in the recommended doses. No adverse reactions are associated with carbidopa; the adverse reactions reported are those related to combination therapy with levodopa or carbidopa-levodopa combination products.
- laboratory monitoring not necessary
- Bismuth Subcitrate Potassium; Metronidazole; Tetracycline
- Bismuth Subsalicylate; Metronidazole; Tetracycline
- Brentuximab vedotin
- Isoniazid, INH
- Isoniazid, INH; Pyrazinamide, PZA; Rifampin
- Isoniazid, INH; Rifampin